Protara Therapeutics (TARA) Non-Current Assets (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Non-Current Assets of $51.9 million for Q1 2026, up 23.55% year-over-year from $42.0 million in Q1 2025, and up 3.93% quarter-over-quarter from $50.0 million in Q4 2025.
Protara Therapeutics (TARA) Non-Current Assets (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Non-Current Assets for 14 consecutive years, with $51.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 23.55% year-over-year to $51.9 million; the TTM figure through Mar 2026 stood at $142.7 million (up 104.57% YoY), while the FY2025 annual figure was $50.0 million, up 437.31% from the prior year.
- Non-Current Assets climbed to $51.9 million in Q1 2026 per TARA's latest filing, from $50.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $70.6 million in Q1 2022 and bottomed at $9.0 million in Q3 2025.
- Historically, Non-Current Assets has averaged $27.5 million across 5 years, with a median of $11.8 million in 2023.
- Annual changes were most pronounced in 2023 — Non-Current Assets plunged 83.29% — and 2025, when it surged 437.31%.
- Protara Therapeutics' Non-Current Assets stood at $27.1 million in 2022, then plunged by 62.24% to $10.2 million in 2023, then declined by 9.27% to $9.3 million in 2024, then soared by 437.31% to $50.0 million in 2025, then climbed by 3.93% to $51.9 million in 2026.
- Business Quant data shows TARA's Non-Current Assets at $51.9 million in Q1 2026, $50.0 million in Q4 2025, and $9.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 29.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.94 Mn |
| Mar 31, 2026 | 51.93 Mn |
| Dec 31, 2025 | 49.96 Mn |
| Sep 30, 2025 | 8.99 Mn |
| Jun 30, 2025 | 31.84 Mn |
| Mar 31, 2025 | 42.03 Mn |
| Dec 31, 2024 | 9.30 Mn |
| Sep 30, 2024 | 9.01 Mn |
| Jun 30, 2024 | 9.43 Mn |
| Mar 31, 2024 | 10.22 Mn |
| Dec 31, 2023 | 10.25 Mn |
| Sep 30, 2023 | 10.65 Mn |
| Jun 30, 2023 | 10.88 Mn |
| Mar 31, 2023 | 11.79 Mn |
| Dec 31, 2022 | 27.14 Mn |
| Sep 30, 2022 | 49.92 Mn |
| Jun 30, 2022 | 53.79 Mn |
| Mar 31, 2022 | 70.57 Mn |
| Dec 31, 2021 | 79.48 Mn |
| Sep 30, 2021 | 85.00 Mn |